ZORYVE Demand Surges, Guidance Raised, Pediatric Psoriasis Approved—Franchise Scaling Confirmed

What happened

Arcutis reported Q2 2026 net product revenue of $129.9 million, up 59% year-over-year and 23% sequentially, handily beating the re-acceleration needed after Q1’s deductible reset. The company raised full-year 2026 guidance to $525–$540 million, reflecting robust demand and confidence in continued growth. FDA approved ZORYVE cream 0.3% for plaque psoriasis in children down to age two, expanding the addressable market. The FDA also accepted the sNDA for ZORYVE cream 0.05% in infants with atopic dermatitis, setting a February 2027 action date. Positive operating cash flow was maintained, reinforcing improving financial leverage.

Implication

With Q2 revenue of $130M and FY26 guidance lifted to $525M–$540M, Arcutis has cleared its key re-acceleration hurdle and demonstrated cash flow generation. The pediatric psoriasis approval and infant AD sNDA acceptance reinforce the long-term growth narrative, while the vitiligo foam program and digital access initiatives offer incremental optionality. Investors should monitor whether sustained script growth and operating leverage can push the stock toward the bull case of $32, but elevated SG&A and eventual generic risks warrant caution. Near-term, the stock may re-rate as the market prices in higher revenue trajectory and reduced execution risk.

Thesis delta

Previous thesis required a Q2 revenue rebound and positive FDA decision to validate the scaling franchise. Both occurred: revenue exceeded the $115M threshold and pediatric psoriasis approval expanded the label, strengthening conviction. The raised guidance and sustained cash flow generation shift the narrative from a 'show-me' re-acceleration to a 'prove-it' growth scalability story.